Inactive Instrument

FARMAFORC

Equities

FFC

AU000000FFC7

FarmaForce Limited Announces Board Changes

November 23, 2015 at 06:01 pm

FarmaForce Limited announced changes to the board with effect immediately. Mr. Daniel Morato submitted his resignation as Executive Director to the board as of November 23, 2015, and is immediately replaced by Dr. George Syrmalis as Non-executive Director. Dr. Syrmalis is Executive Director and Chairman of iQnovate Ltd.

Latest news about FARMAFORC

Farmaforce Limited Announces Partnership with AFT Pharmaceuticals	22-02-22	CI
FarmaForce Limited Announces Executive Changes	22-01-12	CI
Farmaforce Limited Announces Resignation of Dr. George Syrmalis as A Director of the Company	21-11-22	CI
Farmaforce Limited Announces Resignation of Mr. Harry Simeonidis as Non-Executive Director	21-08-30	CI
Farmaforce Limited Reports Earnings Results for the Full Year Ended June 30, 2021	21-08-27	CI
FarmaForce Limited Appoints Vincenzo Milazzo as Director and Chairman	21-06-17	CI
FarmaForce Limited Announces Resignation of George Elias as Chairman and Non-Executive Director	21-06-17	CI
FarmaForce Limited Announces Resignation of Terence Rego as A Non-Executive Director	21-05-24	CI
FarmaForce Limited Announces Executive Changes	21-05-03	CI
FarmaForce Limited Appoints Terence Rego as Director	21-03-21	CI
FarmaForce Limited Reports Earnings Results for the Half Year Ended December 31, 2020	21-02-25	CI
FarmaForce Limited Announces Executive Changes	21-01-13	CI
Farmaforce Limited Reports Earnings Results for the Full Year Ended June 30, 2020	20-08-27	CI
FarmaForce Limited Provides Earnings Guidance for the Second Half and Full Year of 2020	20-03-09	CI
Farmaforce Limited Reports Earnings Results for the Half Year Ended December 31, 2019	20-02-27	CI
Farmaforce Limited Reports Earnings Results for the Full Year Ended June 30, 2019	19-08-30	CI
Farmaforce Limited Reports Earnings Results for the Half Year Ended December 31, 2018	19-02-27	CI
Farmaforce Limited Announces Consolidated Audited Financial Results for the Year Ended June 30, 2018	18-09-30	CI
FarmaForce Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2018	18-08-31	CI
FarmaForce Limited Provides Revenue Guidance for the Financial Year 2018 to 2019	18-06-24	CI
FarmaForce Limited Announces Relocation of Corporate Headquarters and Registered Office	18-02-28	CI
FarmaForce Limited Reports Earnings Results for the Half Year Ended December 31, 2017	18-02-27	CI
91,575,010 Ordinary Shares of FarmaForce Limited are subject to a Lock-Up Agreement Ending on 27-OCT-2017.	17-10-26	CI
900,000 Options of FarmaForce Limited are subject to a Lock-Up Agreement Ending on 27-OCT-2017.	17-10-26	CI
FarmaForce Limited Reports Unaudited Earnings Results for the Year Ended June 30, 2017	17-08-31	CI

Chart FARMAFORC

Duration

Period

More charts

Company Profile

A.C.N. 167 748 843 Limited, formerly Farmaforce Limited, is an Australia-based company, which provides sales, data and medical affairs solutions to the healthcare industry. The Company also provides scalable, customized solutions on demand to its clients. The Company operates through two segments: contract sales and marketing services to external customers, and services to related parties. The Company's data intelligence services include market surveys, geo-mapping, market analysis and sales force analytics. The Company's medical affairs solutions include various services, such as medical science liaisons (MSLs) teams and solutions to meet client's business goals, medical information service for timely response to product related enquiries, pharmacovigilance operations (PV) that ensure compliance with local PV/ product safety regulations. Its medical affairs product pre-launch planning and implementation focused on client's product launch needs and readiness.

Sector

More about the company